Literature DB >> 7857592

Modifications of mesolimbic and nigrostriatal dopaminergic activities after intracerebroventricular administration of prolactin.

M L Hernández1, J J Fernández-Ruiz, M Navarro, R de Miguel, M Cebeira, L Vaticón, J A Ramos.   

Abstract

In the present study we examined the effects of intracerebroventricular (i.c.v.) injections of prolactin (PRL) on the presynaptic activity and post-synaptic sensitivity of mesolimbic and nigrostriatal dopaminergic neurons. In addition, the effects of PRL on in vitro release of dopamine (DA) from perifused striatal fragments were examined. Tyrosine hydroxylase (TH) activity and D2 receptor density in the striatum decreased after i.c.v. PRL administration; this was accompanied by an increase in D2 receptor affinity. These effects occurred after i.c.v. administration of PRL to normoprolactinemic rats, although normally they did not appear after administration to animals with pituitary grafting-induced hyperprolactinemia. Thus, in these animals, i.c.v. PRL failed to decrease TH activity and D1 and D2 receptor densities to a significant extent. In the case of D2 receptors, this was probably due to the fact that pituitary grafting-induced hyperprolactinemia itself was able to reduce the density of this receptor. No changes were observed in DA or L-3, 4-dihydroxyphenylacetic acid (DOPAC) contents after i.c.v. administration of PRL to both normo-and hyperprolactinemic animals. Basal and K(+)-evoked DA release in vitro from perifused striatal fragments of normoprolactinemic rats were not affected by the addition of PRL, whereas this hormone enhanced K(+)-evoked DA release when added to perifused striatal fragments from hyperprolactinemic animals. In the limbic forebrain, i.c.v. administration of PRL to normoprolactinemic animals produced a decrease in DA and DOPAC contents and D1 receptor density. Interestingly, none of these effects appeared when PRL was injected to hyperprolactinemic animals. In summary, our results suggest a possible inhibitory role of PRL on the activity of both the nigrostriatal and mesolimbic dopaminergic neuronal systems. These inhibitory effects were reflected in the decreases elicited in a set of neurochemical parameters, indicating either presynaptic activity or postsynaptic sensitivity, after i.c.v.-administered PRL. This observation supports the hypothesis of a possible neuromodulatory role for an extrapituitary PRL on the activity of these neurons, although the fact that most of these effects did not appear when i.c.v. administration was performed in hyperprolactinemic rats also suggests that they are influenced by peripheral PRL levels.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857592     DOI: 10.1007/bf01277929

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  43 in total

1.  Central prolactin infusions stimulate maternal behavior in steroid-treated, nulliparous female rats.

Authors:  R S Bridges; M Numan; P M Ronsheim; P E Mann; C E Lupini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Subcellular distribution of hypothalamic prolactin-like immunoreactivity.

Authors:  N V Emanuele; L Metcalfe; T Lubrano; H Rubinstein; L Kirsteins; A M Lawrence
Journal:  Brain Res       Date:  1987-03-31       Impact factor: 3.252

3.  Extra-hypothalamic dopamine is not involved in the effects of hyperprolactinemia on male copulatory behavior.

Authors:  P C Doherty; S J Lane; K A Pfeil; W W Morgan; A Bartke; M S Smith
Journal:  Physiol Behav       Date:  1989-06

4.  Immunoreactive prolactin in the rat hypothalamus: in vitro release and subcellular localization.

Authors:  W J DeVito; J M Connors; G A Hedge
Journal:  Neuroendocrinology       Date:  1987-08       Impact factor: 4.914

5.  Distribution of immunoreactive prolactin in the male and female rat brain: effects of hypophysectomy and intraventricular administration of colchicine.

Authors:  W J DeVito
Journal:  Neuroendocrinology       Date:  1988-04       Impact factor: 4.914

6.  Prolactin mRNA exists in rat hypothalamus.

Authors:  B S Schachter; S Durgerian; R E Harlan; D W Pfaff; B D Shivers
Journal:  Endocrinology       Date:  1984-05       Impact factor: 4.736

7.  In vivo voltammetry study of the modulatory action of prolactin on the mesolimbic dopaminergic system.

Authors:  J L Gonzalez-Mora; T Guadalupe; M Mas
Journal:  Brain Res Bull       Date:  1990-11       Impact factor: 4.077

8.  Probable extrapituitary source of the immunoreactive prolactin measured in the cerebrospinal fluid of unanesthetized rats by push-pull cannulation of the 3rd ventricle.

Authors:  G Barbanel; G Ixart; S Arancibia; I Assenmacher
Journal:  Neuroendocrinology       Date:  1986       Impact factor: 4.914

9.  Comparison of the effect of prolactin on dopamine release from the rat dorsal and ventral striatum and from the mediobasal hypothalamus superfused in vitro.

Authors:  J C Chen; V D Ramirez
Journal:  Eur J Pharmacol       Date:  1988-04-27       Impact factor: 4.432

10.  Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain.

Authors:  J Glowinski; L L Iversen
Journal:  J Neurochem       Date:  1966-08       Impact factor: 5.372

View more
  3 in total

Review 1.  Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans.

Authors:  Tillmann H C Krüger; Uwe Hartmann; Manfred Schedlowski
Journal:  World J Urol       Date:  2005-05-12       Impact factor: 4.226

2.  The maternal hormone in the male brain: Sexually dimorphic distribution of prolactin signalling in the mouse brain.

Authors:  Hugo Salais-López; Carmen Agustín-Pavón; Enrique Lanuza; Fernando Martínez-García
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

3.  Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

Authors:  Mehdi Farokhnia; Kelly M Abshire; Aaron Hammer; Sara L Deschaine; Anitha Saravanakumar; Enoch Cobbina; Zhi-Bing You; Carolina L Haass-Koffler; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.